Ignyta, Inc.
🏢 View company profile →25Patents
25Active
25Granted
51Portfolio score
Filing activity: Nov 12, 2013 → Apr 14, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9149464B2 | Bendamustine derivatives and methods of using same | Chemistry; Metallurgy | 26 | Active |
| US9150517B2 | Bendamustine derivatives and methods of using same | Chemistry; Metallurgy | 26 | Active |
| US10231965B2 | Molecules for administration to ROS1 mutant cancer cells | Human Necessities | 7 | Active |
| US10085979B2 | Combinations for the treatment of neuroblastoma | Chemistry; Metallurgy | 7 | Active |
| US9029538B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | Chemistry; Metallurgy | 7 | Active |
| US9120778B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | Chemistry; Metallurgy | 4 | Active |
| US10357490B2 | Combinations for the treatment of neuroblastoma | Chemistry; Metallurgy | 4 | Active |
| US9522902B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | Chemistry; Metallurgy | 3 | Active |
| US9353097B2 | Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor | Chemistry; Metallurgy | 3 | Active |
| US10398693B2 | Pharmaceutical compositions and dosage forms | Human Necessities | 3 | Active |
| US10561651B2 | Methods for treating neuroblastoma | Human Necessities | 3 | Active |
| US9718810B2 | Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor | Chemistry; Metallurgy | 2 | Active |
| US9452988B2 | Bendamustine derivatives and methods of using same | Chemistry; Metallurgy | 2 | Active |
| US11007191B2 | Pharmaceutical compositions and dosage forms | Human Necessities | 1 | Active |
| US10869864B2 | Combinations for the treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US10682348B2 | Molecules for administration to ROS1 mutant cancer cells | Human Necessities | 1 | Active |
| US9630926B2 | Bendamustine derivatives and methods of using same | Chemistry; Metallurgy | 0 | Active |
| US10799503B2 | Methods for the treatment of cancer | Human Necessities | 0 | Active |
| US9914731B2 | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | Human Necessities | 0 | Active |
| US9987281B2 | Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor | Chemistry; Metallurgy | 0 | Active |
| US10028956B2 | Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents | Human Necessities | 0 | Active |
| US10017496B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9913827B2 | Bendamustine derivatives and methods of using same | Chemistry; Metallurgy | 0 | Active |
| US11253515B2 | Pharmaceutical compositions and dosage forms | Human Necessities | 0 | Active |
| US9745283B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.